🔗 Share this article

As the United States continues making historic revisions to its vaccine guidelines, a particular individual has emerged somewhat surprisingly: Høeg, a Danish American physician and public health researcher who initially gained attention by casting doubt on Covid shots during the pandemic and has concentrated on potential deaths following Covid vaccination in her brief time at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Schedule

Public health authorities planned to announce radical changes to the pediatric immunization program in December, aligning the US with the Danish vaccine program, according to reports – a substantial departure that would place the US at odds with much of the international standard with insufficient data for public health gain. The announcement has been delayed until the next year.

Instead of the director of the vaccine center, Høeg is listed to present at the gathering. She was just designated acting director of the FDA’s CDER, the fifth individual to head the division this year.

A New Direction at the Regulatory Body

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad solidify control at the FDA – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for halting some pediatric shot schedules in the US to become more in line with Denmark, a society with comprehensive healthcare and a citizenry roughly the population of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – traditionally the purview of Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Background

The appointee has no obvious background in pharmaceutical research, oversight or management, which has been standard for former directors of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous heads of the center would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that former directors who headed the center have had.”

CDER has an enormous workload at the agency, the former commissioner pointed out.

“Everybody just zeroes in on the innovative therapies, but the generic program clears numerous generic drugs. There is also a biologic copycat branch, OTC medication office and more, and each of these need to be managed,” Woodcock noted. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a substantial administrative component to the position, which manages more than 5,000 staff members. “It’s a enormous management job, if you perform it correctly,” Woodcock said.

Response and Controversial Programs

When asked about concerns about Høeg’s qualifications and whether this selection indicates greater collaboration among regulatory chiefs on vaccines, a press secretary responded that the “inquiries rely on inaccurate assumptions”.

“Her resume aligns with the functions of her position,” the official said, noting the time Dr. Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a contentious expedited drug-approval program that apparently worried her former heads. “How are these medications being chosen for this expedited pathway? Who makes the decisions?” Howard asked. “There is a lot of lack of transparency occurring at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards laxer oversight of most medications, except for immunizations.”

Established Track Record on Immunizations

Regarding vaccines, Høeg has a more established, if concerning, history, critics said. She published a analysis using non-validated crowd-sourced reports to assess the frequency of myocarditis after COVID-19 immunization. She advised the Florida top health official Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the incoming administration included altering rules for new vaccines and halting “unnecessary” immunizations, she stated following the vote on a audio program. At the FDA, Høeg has according to sources suggested excluding adolescent males from obtaining Covid vaccines.

“She is an thorough dogmatist who starts off with her preconceived notions and tailors the evidence to fit the data in a extremely deceptive, untruthful way,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of fellow dissenters, {like|